The Lynx Group
Cholangiocarcinoma News

Comparison of the Clinical Features, Treatment Patterns, and Tumor Mutations of Patients with Intrahepatic and Extrahepatic CCA

2020 Year in Review: Cholangiocarcinoma — December 19, 2020

Retrospective chart review data indicate that intrahepatic CCA and extrahepatic CCA exhibit disparate clinical features and molecular profile, and divergent treatment patterns.

To inform treatment decision, better insights on the clinical and molecular features distinguishing patients with intrahepatic CCA and extrahepatic CCA are warranted. Results of a retrospective chart review that compared the clinicopathologic and molecular characteristics of intrahepatic CCA and extrahepatic CCA as well as treatment patterns were reported at the ASCO 2020 Gastrointestinal Cancers Symposium and summarized here.

A retrospective chart review was performed at 8 institutions on patients with histologically confirmed intrahepatic CCA or extrahepatic CCA diagnosed after June 2009. Information relating to demographics, risk factors, treatments, pathology, and OS was collected. Molecular profiling of tumor tissue was also performed.

A total of 737 patients with CCA were enrolled. Of these, 538 (73%) had a diagnosis of intrahepatic CCA and 199 (27%) had extrahepatic CCA. Compared with the extrahepatic CCA cohort, patients in the intrahepatic CCA cohort were significantly more likely to be female (52% vs 42%; P = .013), present with lymph node metastasis (35% vs 22%; P = .0004), have solid organ metastasis primarily to the liver (85% vs 58%; P <.0001) or lung (37% vs 14%; P = .0011), have tumors ≥5 cm at resection (47.5% vs 5%; P <.0001), and have a larger tumor size (5.5 cm vs 2.5 cm; P <.0001). In terms of treatment pattern, patients in the intrahepatic CCA cohort more often received liver-directed therapy (45% vs 26%; P = .0004), targeted therapy (17% vs 4%; P = .0002), and were more often enrolled in a clinical trial (23% vs 11%; P = .004). In comparison with the intrahepatic CCA cohort, patients in the extrahepatic CCA cohort were more likely to be male (58% vs 48%; P = .013), have peritoneal metastasis (35% vs 25%; P = .0343), undergone surgery (55% vs 30%; P <.0001), and receive adjuvant chemoradiation (80% vs 29%; P <.0001).

Mutation profiling was performed in 381 (52%) patients. Of these, 301 patients had intrahepatic CCA and 80 had extrahepatic CCA. The findings of the molecular analysis indicated that patients with intrahepatic CCA were significantly more likely to have IDH1 mutations (P <.0001) and FGFR2 fusions (P = .0004), whereas patients with extrahepatic CCA were more likely to have KRAS mutations (P = .0004), APC mutations (P = .0027), SMAD4 mutations (P = .0051), and TP53 mutations (P = .043).

These data indicate that patients with intrahepatic CCA and extrahepatic CCA show differences in their clinical features and molecular profiling, leading to disparate treatment patterns.

Source: Pappas L, et al. J Clin Oncol. 2020;38(4_suppl). Abstract 580.

Related Items

Phase 1 Results of Gunagratinib in Patients with Advanced Solid Tumors Harboring FGFR Pathway Alterations
2021 Year in Review: Cholangiocarcinoma
A phase 1/2a, first-in-human clinical study demonstrated that the highly selective, irreversible pan-FGFR inhibitor gunagratinib was safe and well-tolerated in patients with advanced solid tumors, including CCA.
Prognostic Value of FGFR2 Alterations in Patients Receiving Systemic Chemotherapy for Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis indicated the prognostic value of FGFR2 fusions/rearrangements in patients with intrahepatic CCA receiving systemic chemotherapy, which warrants additional study.
FGFR2 Fusion and/or Rearrangement Profiling in Chinese Patients with Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Epidemiologic data assessed the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with intrahepatic CCA, including those with heterogeneous FGFR2 partner genes.
A Comprehensive Genomic and Immune Profiling Study of IDH1- and IDH2-Driven Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A comprehensive genomic and immune characterization of IDH-mutated and wild-type intrahepatic CCA revealed significant differences in genetic alterations.
Characteristics of IDH Mutations in Bile Duct Carcinoma in a Chinese Population
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis in a large Chinese patient cohort with bile duct carcinoma indicated that activating IDH1/2 mutations occurred at a lower rate compared with that previously reported in the global population.
Silmitasertib (CX-4945) plus Gemcitabine and Cisplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic CCA
2021 Year in Review: Cholangiocarcinoma
Preliminary evidence suggests that combination treatment with silmitasertib plus gemcitabine/cisplatin as first-line therapy has promising efficacy and a favorable safety profile in patients with locally advanced or metastatic CCA.
Targeted Therapies in CCA: Assessment of US Oncologist Practice Patterns
2021 Year in Review: Cholangiocarcinoma
Findings from a clinical practice assessment identified gaps in knowledge, competence, and confidence regarding testing and the use of targeted therapies in patients with unresectable CCA, underscoring the important role of education in overcoming these gaps.
First-Line Toripalimab plus Lenvatinib in Combination with GemOx Chemotherapy for Advanced Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Results of a phase 2 study indicate that toripalimab and lenvatinib in combination with GemOx chemotherapy provide antitumor activity and reasonable tolerability in patients with advanced intrahepatic CCA.
Comparative Landscape of Actionable Somatic Alterations in Advanced CCA from Circulating Tumor and Tissue-Based DNA Profiling
2021 Year in Review: Cholangiocarcinoma
Findings from a retrospective analysis support the use of both tissue and liquid biopsy biomarker testing to guide therapy selection in patients with advanced CCA, particularly when tissue may not be readily available.
Tibsovo (Ivosidenib) FDA Approved for Advanced or Metastatic Cholangiocarcinoma and IDH1 Mutation
By Loretta Fala
2021 Year in Review: Cholangiocarcinoma
Cholangiocarcinoma (CCA) is an aggressive cancer of the bile duct that forms inside the liver (ie, intrahepatic) or outside the liver (ie, extrahepatic, including perihilar and distal tumors). Individuals with colitis or certain liver diseases may have an increased risk for CCA. Although the precise incidence of CCA is unknown, an estimated 8000 new cases of CCA are diagnosed annually in the United States. It is likely, however, that this number is higher, because CCA is difficult to diagnose and may be misclassified at times.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: